Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Genomic Research Center, |
RCV000714644 | SCV000845360 | uncertain significance | 2-aminoadipic 2-oxoadipic aciduria | 2018-08-07 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000714644 | SCV002307855 | uncertain significance | 2-aminoadipic 2-oxoadipic aciduria | 2024-01-03 | criteria provided, single submitter | clinical testing | This sequence change replaces proline, which is neutral and non-polar, with leucine, which is neutral and non-polar, at codon 35 of the DHTKD1 protein (p.Pro35Leu). This variant is present in population databases (rs753355529, gnomAD 0.009%). This variant has not been reported in the literature in individuals affected with DHTKD1-related conditions. ClinVar contains an entry for this variant (Variation ID: 587471). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be disruptive. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Ambry Genetics | RCV002534525 | SCV003701782 | uncertain significance | Inborn genetic diseases | 2022-12-01 | criteria provided, single submitter | clinical testing | The c.104C>T (p.P35L) alteration is located in exon 1 (coding exon 1) of the DHTKD1 gene. This alteration results from a C to T substitution at nucleotide position 104, causing the proline (P) at amino acid position 35 to be replaced by a leucine (L). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Ce |
RCV003884714 | SCV004698460 | uncertain significance | not provided | 2024-02-01 | criteria provided, single submitter | clinical testing |